Cargando…
Histone deacetylase inhibitors: clinical implications for hematological malignancies
Histone modifications have widely been implicated in cancer development and progression and are potentially reversible by drug treatments. The N-terminal tails of each histone extend outward through the DNA strand containing amino acid residues modified by posttranslational acetylation, methylation,...
Autores principales: | Tambaro, Francesco Paolo, Dell’Aversana, Carmela, Carafa, Vincenzo, Nebbioso, Angela, Radic, Branka, Ferrara, Felicetto, Altucci, Lucia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365365/ https://www.ncbi.nlm.nih.gov/pubmed/22704087 http://dx.doi.org/10.1007/s13148-010-0006-2 |
Ejemplares similares
-
Cancer epigenetics: Moving forward
por: Nebbioso, Angela, et al.
Publicado: (2018) -
HDAC Inhibitors Repress BARD1 Isoform Expression in Acute Myeloid Leukemia Cells via Activation of miR-19a and/or b
por: Lepore, Ilaria, et al.
Publicado: (2013) -
Dual Tumor Suppressor and Tumor Promoter Action of Sirtuins in Determining Malignant Phenotype
por: Carafa, Vincenzo, et al.
Publicado: (2019) -
miRNA-mediated deregulation in leukemia
por: Dell’Aversana, Carmela, et al.
Publicado: (2012) -
Sirtuins and Disease: The Road Ahead
por: Carafa, Vincenzo, et al.
Publicado: (2012)